Iskia: Therapeutic Focus and Clinical Utility

Iskia is utilized in the treatment of newly diagnosed multiple myeloma (NDMM) in patients who are eligible for autologous stem cell transplantation (ASCT). This patient population receives Iskia as part of a combination regimen involving isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd).

---

Main Uses and Benefits

Iskia's primary therapeutic purpose is to enhance the depth of response against multiple myeloma, a type of plasma cell dyscrasia. Clinical data indicates that the addition of isatuximab to the KRd backbone significantly increases the rate of measurable residual disease (MRD) negativity in patients. MRD negativity after consolidation therapy is an objective measure indicating a very deep response to treatment. Achieving this deeper level of response with Iskia may lead to improved progression-free survival outcomes for patients with newly diagnosed multiple myeloma.

---

Quick Facts

• Treats: Newly diagnosed multiple myeloma (NDMM).
• Used In: Patients eligible for autologous stem cell transplantation (ASCT).
• Goal: Achieves high rates of measurable residual disease (MRD) negativity.
• Primary Benefit: Provides a deeper level of response, which may correlate with improved progression-free survival.

Regulatory References

1. EMA therapeutic overview

Who Can and Cannot Use Iskia?

The official eligibility profile for the Iskia regimen (Isatuximab, Carfilzomib, Lenalidomide, and Dexamethasone) is strictly defined by regulatory documents governing its combination components.

---

Absolute Contraindications

The medicine is contraindicated in women who are pregnant due to the severe, documented risk of embryo-fetal toxicity. Patients with a known history of severe hypersensitivity to isatuximab, lenalidomide, or any of the product's inactive ingredients must not use this medicine. Furthermore, compliance with the mandatory contraception and testing requirements of the regulatory Risk Evaluation and Mitigation Strategy (REMS) program is a strict condition of eligibility for both males and females of reproductive potential.

---

Conditional Eligibility and Restrictions

The regimen is intended solely for adult patients (aged 18 years and older). Use in the pediatric population is not established due to insufficient safety and effectiveness data. Eligibility is conditional upon the patient's organ function status; those with renal or hepatic impairment require official dose adjustments as specified in the product labeling. Patients with pre-existing cardiac conditions or risk factors for thromboembolism are considered restricted populations who must adhere to specific, labeled management protocols. Breastfeeding is not recommended during treatment.

Interactions with other medicines and products

Contraindicated Combinations

The co-administration of Iskia (Acetylsalicylic acid, ASA) is formally contraindicated with methotrexate at doses ge 15 mg/week due to the risk of increased methotrexate toxicity. An additional contraindication applies to oral anticoagulants in patients with a history of gastro-duodenal ulcers due to a significantly increased haemorrhage risk.

Pharmacodynamic and Exposure-Altering Interactions

ASA poses a documented Pharmacodynamic (PD) risk when combined with anticoagulants, heparins, and other antiplatelet agents, due to an additive effect that increases the documented risk of bleeding. The combination with other Non-Steroidal Anti-Inflammatory Drugs (NSAIDs) also increases the risk of gastrointestinal ulcers and haemorrhage. ASA causes a reduction in renal clearance for certain medicines, including methotrexate, digoxin, and lithium, leading to elevated plasma exposure of those agents. ASA may also reduce the effect of uricosurics by competing for elimination in the renal tubules.

Timing and Population Constraints

Regulatory guidance specifies a timing separation rule to mitigate interference with the antiplatelet effect of low-dose ASA: ibuprofen should be taken at least 8 hours before or at least 30 minutes after the immediate-release ASA dose. The official profile notes that interaction risks, such as the increased risk of haemorrhage with Low Molecular Weight Heparins, are heightened in elderly patients. The interaction with pemetrexed, resulting in decreased clearance, is specific to patients with mild to moderate renal insufficiency.

Iskia's mechanism is defined by the irreversible modulation of specific biological pathways, resulting in measurable physiological changes. The drug's core molecular action is the permanent disabling of the Cyclooxygenase (COX-1 and COX-2) enzymes through covalent binding known as acetylation. This unique, time-dependent inhibitory mechanism blocks the Arachidonic Acid Cascade at the cyclooxygenase step, preventing the formation of prostanoid signaling molecules.

---

The antipyretic pathway effect arises from the central suppression of Prostaglandin E2 ( PGE2) synthesis within the hypothalamic thermoregulatory center of the brain. This action removes the chemical signal responsible for elevating the body's temperature set point.

---

The mechanism exhibits a critical functional constraint based on cell type. The permanent inactivation of COX-1 in anucleate cells (platelets) results in a lasting suppression of TXA2 synthesis in these cells. Conversely, the inhibition in nucleated cells is temporary as they can synthesize new enzyme molecules, modulating the duration of the systemic effect.

Iskia is administered exclusively via Intravenous (IV) infusion and must be performed in a specialized healthcare setting under the direct supervision of a healthcare professional. The regimen follows a cyclic schedule as part of a combination therapy for newly diagnosed multiple myeloma. The dose is precisely calculated based on the patient’s actual body weight at the time of administration, with the standard dose being 10 mg per kilogram of body weight.

The treatment schedule is divided into phases. Iskia is typically given once weekly during the initial cycle, then transitions to less frequent administration, generally every two weeks, in subsequent cycles. In some long-term continuous regimens, dosing may be extended further to every four weeks. Treatment is continued following this structured schedule until disease progression or development of unacceptable toxicity.

A critical step before each infusion is the administration of mandatory premedication 15 to 60 minutes prior to starting Iskia. This is a procedural requirement. The active ingredient is supplied as a solution that requires dilution in an IV bag of 0.9% Sodium Chloride or 5% Dextrose. The infusion must be delivered through a 0.22-micron in-line filter. The infusion rate is carefully controlled, starting slower for the first dose and gradually increasing for subsequent doses if well-tolerated. If a scheduled dose is missed, it should be administered as soon as possible, and the overall treatment calendar adjusted to maintain the correct interval between doses.

Research Evidence / Overview of Studies for Iskia

The active substance in Iskia (Acetylsalicylic acid) is mentioned in the quick facts, but the specific clinical research provided focuses exclusively on the combination regimen using the name "Iskia." Research for Iskia, as a component of a specific combination therapy (Isa-KRd), focuses on its inclusion in this regimen. The research base involves controlled studies that examine outcomes related to newly diagnosed multiple myeloma in the studied population.

---

Evidence for Use in Newly Diagnosed Multiple Myeloma (NDMM)

The research was conducted using Phase III randomized controlled trials (RCTs), which compared the Isa-KRd regimen against a control regimen (KRd). Studies involved adult patients with newly diagnosed disease who met specific criteria for transplantation eligibility. The studies also evaluated the impact of the regimen on specific clinical outcomes, such as progression-free survival (PFS).

In the pivotal clinical trials, researchers’ main focus was to determine the frequency with which patients achieved MRD negativity after completing consolidation treatment. MRD negativity is a biomarker that measures the absence of detectable myeloma cells in the bone marrow, using highly sensitive testing methods. Studies described patterns related to achieving these specific response rates in the observed populations following the full course of induction and consolidation therapy.

---

Long-Term Evidence and What is Still Uncertain About the Research

Studies monitored patient outcomes over defined time intervals to observe the potential durability of the initial response. Studies explored the duration of time patients remained free from disease progression. The initial follow-up durations were short when the primary findings were first reported. Therefore, long-term effects on overall survival are not fully established, and data are still emerging as the trials continue to track patients over extended periods.

A key research limitation is that the results apply specifically to the combination regimen (Isa-KRd). The evidence does not provide data on Iskia's contribution as a single agent in this context. Furthermore, while the research provides insight into short-term changes and the measured response rates, long-term outcomes are not fully established. Data are still required to analyze the correlation between the MRD negativity biomarker and long-term patient outcomes.

Key Studies & References

1. World Health Organization (WHO) Model List of Essential Medicines
2. Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) vs KRd as induction and consolidation therapy in transplant-eligible newly diagnosed multiple myeloma: results from the phase 3 IsKia trial (Trial registration or subsequent publication)
3. Acetylsalicylic acid - Drug classification and uses, MedlinePlus

Common questions about Iskia (FAQ)

Q: How quickly does Iskia typically start to work?

A: The time it takes for Iskia to start working depends on its purpose. The active ingredient is associated with a rapid onset for its anti-clotting or pain-relief effects, which has been observed within 30 minutes in regulatory studies. However, for its primary use in the multiple myeloma regimen, the full therapeutic effect is evaluated over several treatment cycles as defined in the clinical trials.

Q: Can children or teenagers use Iskia?

A: Official warnings exist regarding a rare but serious condition called Reye's syndrome in children and teenagers, especially if they are recovering from a viral illness. Due to this risk, official documentation indicates the product is generally restricted or not indicated for use in the pediatric population.

Q: Is Iskia safe to use while pregnant or breastfeeding?

A: Regulatory guidance indicates that the use of NSAIDs, which include the active ingredient in Iskia, is not recommended during pregnancy, particularly after 20 weeks gestation, due to potential risks to the developing fetus. Additionally, breastfeeding is generally not recommended while taking this medication.

Q: How long after starting Iskia can I expect to see the full effect?

A: The clinical response to the multiple myeloma regimen is evaluated over time. Clinical outcomes, such as achieving MRD negativity (no detectable cancer cells) and progression-free survival (PFS), are typically measured after the full course of induction and consolidation therapy as performed in the clinical studies.

Q: Can older adults use Iskia safely?

A: Official labels note that certain interaction risks, such as increased bleeding or toxicity, can be heightened in elderly patients. Due to potential changes in kidney function, monitoring may be relevant for appropriate dose selection in this population.

Q: How does the body process or break down Iskia?

A: The body processes Iskia's active ingredient quickly in the bloodstream, converting it into salicylic acid. This is primarily metabolized (broken down) by the liver and is eliminated mainly through the kidneys.

Q: What is the difference between the low dose and high dose of Iskia?

A: The active ingredient in Iskia has what are known as dose-dependent effects. Lower doses are primarily intended to reduce clotting by inhibiting one specific enzyme (COX-1), while higher doses also inhibit a second enzyme (COX-2) to achieve general pain and anti-inflammatory effects.

Q: How long does Iskia stay in your system after stopping?

A: While the chemical half-life of the active ingredient is relatively short, its functional anti-clotting effect on blood platelets is permanent. This effect lasts for the entire lifespan of the affected platelet, which is typically about 7 to 10 days.

Q: Do you need a special prescription or monitoring for Iskia?

A: Administration is required in a specialized healthcare setting under direct supervision. Official labels indicate that monitoring of complete blood cell counts is a required procedure during treatment, and specific blood tests are typically required prior to starting treatment.

Q: What is the purpose of the boxed warning on Iskia's labeling?

A: Official labeling includes warnings to draw attention to potential serious risks. These include risks of severe bleeding events, like gastrointestinal hemorrhage, and the rare risk of Reye's syndrome in children/teens. Warnings also address severe risks specific to the multiple myeloma component, such as infusion-related reactions.

Q: What research is currently being done on Iskia?

A: Clinical trials examining the combination regimen continue to follow patients over extended periods. This ongoing research tracks long-term outcomes, such as overall survival and the durability of the initial treatment response observed in the studied population.

Q: Is Iskia the same type of drug as [Similar Drug Name]?

A: Official documents classify the drug's active ingredient as a non-steroidal anti-inflammatory drug (NSAID). It is also scientifically described as a cyclooxygenase (COX) enzyme inhibitor.

Q: Is there a generic version of Iskia available?

A: The active ingredient, Acetylsalicylic acid (ASA), is widely available in generic form for its standalone uses. However, the specific combination product, Iskia, may only be available as a brand-name product for the multiple myeloma indication.

Q: What is the shelf life of Iskia tablets?

A: The product is supplied as a solution for Intravenous (IV) infusion and is not available in tablet form. Specific shelf life and storage information for the solution is always included within the official product labeling.

Q: Do I need to get blood tests while taking Iskia?

A: Monitoring procedures are indicated during treatment. Regulatory documents for the combination regimen component often require periodic monitoring of complete blood cell counts. The active ingredient itself is also associated with changes in certain laboratory results that require tracking.

Q: Why is Iskia used for more than one health issue?

A: The active ingredient, Acetylsalicylic acid (ASA), is a non-selective enzyme inhibitor commonly known to treat more than one health issue. It is used for its separate effects on pain relief, fever reduction, and anti-clotting.

Q: Does Iskia interact with herbal supplements like St. John's Wort?

A: Regulatory guidance indicates caution regarding herbal supplements like St. John's Wort. Official labeling suggests avoiding its use as it is associated with a potential reduction in the effect of certain co-administered agents within the full treatment regimen.

Q: Why do official documents mention [Specific Safety Classification] for Iskia?

A: Official documents use various warnings and classifications to highlight potential serious adverse reactions. These include risks of severe gastrointestinal hemorrhage and drug-specific risks like infusion-related reactions and low blood cell counts (neutropenia).

Q: Does Iskia require any special storage conditions?

A: Yes, the intravenous solution typically requires specific storage conditions to maintain its potency and stability. This may include requirements for refrigeration, protection from light, or maintaining a controlled room temperature.

Q: Are there any restrictions on alcohol consumption while on Iskia?

A: Restrictions on alcohol consumption are noted in the official labeling. Official recommendations indicate limiting or avoiding alcohol consumption due to the known risk of significantly increased gastrointestinal bleeding caused by the active ingredient.

Q: Where can I find the official patient information leaflet for Iskia?

A: The official patient information leaflet or Medication Guide is published by regulatory authorities. You can typically find this document on the public websites of agencies like the FDA (DailyMed) or EMA, where the Summary of Product Characteristics (SmPC) is located.

Q: Does taking Iskia affect the results of common lab tests?

A: The drug and its active ingredient can potentially affect laboratory test results. This includes changes in liver and kidney values, as well as interference with certain serological tests used for blood typing.

Q: Is Iskia an antibiotic or an antiviral?

A: The drug's active ingredient is classified as a non-steroidal anti-inflammatory drug (NSAID) and is also used as an anti-clotting agent. It is not an antibiotic (used for bacteria) or an antiviral (used for viruses).

Q: What are the potential effects of an Iskia overdose?

A: The potential effects of an overdose of the active ingredient are well-documented. Symptoms may include ringing in the ears (tinnitus), dizziness, vomiting, and confusion. An overdose is a serious medical event that requires immediate medical assessment and management.

Q: How do you dispose of unused or expired Iskia?

A: Official instructions indicate that any unused portion of the intravenous infusion solution is generally discarded. General guidance for the safe disposal of unused or expired medication is available from government regulatory agencies.

Official Storage and Handling Requirements

Iskia (isatuximab-irfc) injection must be stored in a refrigerator at a temperature between 2 C and 8 C (36 F to 46 F). The unopened vial must be kept in its original carton to protect the solution from light.

Regulatory labeling strictly prohibits freezing the vial and advises that the product must not be shaken.

Stability and Disposal

Once the product is prepared for infusion, the diluted solution's total storage time (including preparation and administration) must not exceed 24 hours. This time limit applies whether the solution is refrigerated or stored at room temperature. Any unused product or associated waste material must be disposed of according to local requirements for cytotoxic medicinal products. Furthermore, the medicine must be stored out of the sight and reach of children.